Pitavastatin tablets recalled after failing impurity and degradation specifications
Pitavastatin Tablets 1 mg from AvKARE are being recalled because they failed impurity and degradation specifications. 1,560 bottles are affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III recall for an out-of-specification impurity result with no named impurity, measured level or health consequence stated.
Plain-English summary
Pitavastatin Tablets, 1 mg, 90 tablets per bottle, prescription only, manufactured for AvKARE of Pulaski, Tennessee, NDC 42291-905-90, are being recalled. The action covers 1,560 bottles.
The stated reason is that the product failed impurity and degradation specifications. The FDA classified the action as Class III, its least serious classification. The source does not name the impurity or state a measured level.
Affected lots include 46208 expiring 10/31/2025, 47738 expiring 09/30/2026 and 46943 expiring 05/31/2026, together with the further lots listed in the recall notice. Distribution was nationwide in the USA.
Patients holding affected lots should speak to their pharmacist before stopping treatment, and pharmacies should follow the instructions issued by AvKARE.
The recalled product
- Product
- PITAVASTATIN (PITAVASTATIN CALCIUM)
- Brand
- PITAVASTATIN
- Manufacturer
- AvKARE
- Category
- Drug — Oral tablet
- Affected units
- 1,560
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot
- expiry: Lot 46208
- exp 10/31/2025
- Lot 47738
- exp 09/30/2026
- Lot 46943
- exp 05/31/2026
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by AvKARE under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · PITAVASTATIN
- LowPitavastatin tablets recalled for failed impurities and degradation specifications
FDA (Drugs) · 2025-07-09
- ModerateTeva pitavastatin tablets recalled after failing impurity and degradation specifications
FDA (Drugs) · 2025-07-09
- LowPitavastatin Tablets Recalled for Failed Impurity and Degradation Specifications
FDA (Drugs) · 2025-07-09
Same manufacturer · AvKARE
See all →- HighAmantadine hydrochloride capsules recalled after failing dissolution specifications
FDA (Drugs) · 2026-03-04
- ModerateRosuvastatin tablets recalled after failing a dissolution specification
FDA (Drugs) · 2026-01-14
- HighOral contraceptive tablets recalled after failing content uniformity specifications
FDA (Drugs) · 2025-10-15
- HighAvKare chlorpromazine 100 mg cartons recalled over presence of foreign substance
FDA (Drugs) · 2025-09-17
- HighAvKare chlorpromazine unit dose cartons recalled over presence of foreign substance
FDA (Drugs) · 2025-09-17
Same hazard · impurity specification
See all →- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- ModerateCephalexin Oral Suspension Recalled for Failed Impurities Specifications
FDA (Drugs) · 2025-06-18
- ModerateCephalexin Oral Suspension Recalled for Failed Impurity Specifications
FDA (Drugs) · 2025-06-18
- ModerateH.E.B Allergy Relief Fexofenadine Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2022-01-12
- ModerateHealth Mart Fexofenadine Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2022-01-12